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One of the first uses of the term “fructose” was in 1857 by William Allen Miller FRS, 6 
and it was already known then that fructose was a distinctive carbohydrate, 7 
characterised by sweet taste (Miller, 1957). In most circumstances dietary free sugars 8 
can also be classified as fructose-containing carbohydrates (e.g. sucrose, high-9 
fructose corn syrup), and the fructose component of these sugars is thought to be 10 
primarily responsible for unique metabolic effects. The role of sugars in the diet could 11 
be viewed as contentious, with many arguing that dietary sugar is the cause of type 2 12 
diabetes and obesity (Bray & Popkin, 2014), whereas others posit that dietary sugars 13 
are innocuous to healthy individuals (Archer, 2018). One reason for this confusion and 14 
conflict is that much evidence presented is observational and/or based upon self-15 
report assessments of dietary intake or physical activity. This is a problem, because 16 
observational data can never definitely establish cause-and-effect and can lead to 17 
spurious, misleading correlations. Furthermore, self-report methods are subject to 18 
observation and reporting biases. Herein lies the potential for a physiological approach 19 
to solve some of this confusion and conflict.  20 
By understanding mechanistic links, we can explain some apparent 21 
discrepancies in observational data, and also take a step towards establishing 22 
causality. Plausible physiological links can increase confidence in causality of a 23 
behaviour when randomized controlled trials with hard endpoints would be considered 24 
unethical or impossible to perform. For example, it might be deemed unethical to 25 
randomise people to high versus low fructose intakes for decades to establish whether 26 
fructose intake causes type 2 diabetes or cardiovascular disease. However, by 27 
assessing the effects of fructose intake of physiological process that underlie disease 28 
risk, shorter-term studies can be used to establish causal effects of fructose intake, 29 
without necessarily affecting long-term health risk.  30 
“Fructose in Physiology: Friend or Foe” was the title of a Symposium delivered 31 
at Europhysiology 2018 in London (UK), and was supported by The Journal of 32 
Physiology. The aim of this symposium was to bring together leading researchers 33 
across various career stages to discuss the physiology of fructose metabolism in 34 
health and disease. In doing so, this symposium highlighted the potential mechanisms 1 
by which fructose may exert metabolic effects within specific populations, thereby 2 
overcoming some of the confusion around fructose and health. 3 
Pinnick and Hodson (2019) describe the potential tissue- and sex-specific 4 
effects of fructose metabolism. Short-term (<7 days) high-fructose intake can increase 5 
plasma triglyceride concentrations and intrahepatic fat content, which are implicated 6 
in metabolic disease risk (Pinnick & Hodson, 2019). The mechanisms by which high 7 
fructose intake increases plasma triglyceride concentrations includes hepatic de novo 8 
lipogenesis (DNL) and fatty acid oxidation (Pinnick & Hodson, 2019). A novel focus 9 
was the discussion of the potential effects of fructose on adipose tissue metabolism, 10 
which could be direct or indirect (Pinnick & Hodson, 2019). The classical view is that 11 
the splanchnic tissues are the primary site of fructose metabolism (Gonzalez & Betts, 12 
2018), and therefore adipose tissue is unlikely to be directly affected by fructose 13 
intake. Nevertheless, fructose could indirectly affect adipose tissue metabolism via 14 
increased plasma lactate concentrations following fructose consumption (Liu et al., 15 
2009; Gonzalez et al., 2015). Furthermore, there is potential for some direct effects of 16 
fructose on adipose tissue, since it has been recently estimated that ~15% of a 30-g 17 
oral fructose load can escape first-pass splanchnic metabolism and thereby be 18 
exposed to peripheral tissues (Francey et al., 2019). In addition to evidence that 19 
adipose tissue expresses the fructose-specific transporter, GLUT5, it is plausible that 20 
fructose could have some direct effects on adipose tissue, and this will be an important 21 
avenue for future research (Pinnick & Hodson, 2019). With respect to sex-specific 22 
responses, there is some evidence that males may display greater metabolic 23 
perturbations to high fructose intake when compared to females, including increased 24 
incorporation of fructose carbons into very low-density lipoprotein (VLDL)-TAG 25 
palmitate (reflective of hepatic DNL), greater suppression of fat oxidation, and 26 
increased basal endogenous glucose production (Pinnick & Hodson, 2019). However, 27 
other work has shown that females displayed higher hepatic DNL than males, when 28 
assessed using deuterium oxide (Low et al., 2018). The discrepancies between 29 
studies may be explained by doses of fructose ingested (absolute vs normalised to 30 
fat-free mass), the method of assessing hepatic DNL, or participant characteristics 31 
and background diet. Accordingly, fructose can clearly stimulate lipogenesis in 32 
hepatocytes, but there is a need to further understand the sex-specific effects of 33 
fructose intake on metabolism and health. 34 
Von Holstein-Rathlou and Gillum (2019) discuss a key potential regulator of 1 
fructose intake, fibroblast growth factor 21 (FGF21). FGF21 is a hepatically-derived 2 
hormone that, in mice, can be produced in response to low-protein and ketogenic 3 
diets, fructose feeding and ethanol (von Holstein-Rathlou & Gillum, 2019). It has also 4 
been shown that FGF21 preferentially inhibits ad libitum consumption of sugars and 5 
ethanol in mice, without affecting the intake of other dietary nutrients such as non-6 
sugar carbohydrates, fat and protein, thereby exerting negative-feedback (von 7 
Holstein-Rathlou & Gillum, 2019). In humans, ingestion of sugars and ethanol can also 8 
stimulate FGF21 secretion, and genetic variants in the FGF locus have been 9 
associated with reported intakes of sweet foods (Søberg et al., 2017). The potential 10 
mechanisms by which FGF21 is thought to regulate feeding behaviours is thought to 11 
involve the activation of the FGF21 receptor complex (comprising FGF receptor 1c 12 
and beta-klotho) in the paraventricular nucleus of the hypothalamus (von Holstein-13 
Rathlou & Gillum, 2019). This opens up the intriguing possibility of reducing free-living 14 
sugar (and ethanol) intakes by treatment with FGF21 or by making use of other 15 
strategies that can increase endogenous FGF21 production. 16 
Fuchs et al. (2019) describe how athletes can exploit some of the metabolic 17 
effects of fructose to benefit endurance performance and recovery. Intestinal fructose 18 
absorption primarily occurs via GLUT5. This contrasts with glucose, which is primarily 19 
absorbed via the sodium-dependent glucose transporter, SGLT1 (Fuchs et al., 2019). 20 
Since SGLT1 is thought to be saturable at a rate of 1 g/min this can limit the amount 21 
of exogenous carbohydrate that athletes can ingest and metabolise during exercise. 22 
However, by combining fructose with glucose it is possible to make use of both of 23 
these intestinal transport pathways and thereby deliver more exogenous carbohydrate 24 
to the circulation, whilst also decreasing gastrointestinal discomfort associated with 25 
ingestion of large amounts of carbohydrate during exercise (Gonzalez et al., 2015; 26 
Fuchs et al., 2019). A higher availability of carbohydrates during exercise can have 27 
performance benefits in many endurance sports, thereby highlighting a potential 28 
beneficial role of fructose-containing carbohydrates. Furthermore, rapid restoration of 29 
depleted glycogen stores is a key factor dictating recovery time in multi-stage 30 
endurance events. Since fructose can potently stimulate hepatic glycogen synthesis 31 
(Fuchs et al., 2016) there is potential for fructose-containing carbohydrates to 32 
accelerate recovery. Indeed, when the total amount of carbohydrate is matched, the 33 
ingestion of fructose-glucose mixtures can double the rate of liver glycogen repletion 34 
in recovery from exercise, when compared to glucose-based carbohydrates (Fuchs et 1 
al., 2019). Furthermore, ingestion of fructose-containing carbohydrates during 2 
recovery from exercise can enhance subsequent endurance running capacity, when 3 
compared to glucose-based carbohydrates (Maunder et al., 2018). Therefore, at least 4 
for specific scenarios, fructose-containing carbohydrate can be useful for athletic 5 
performance. 6 
Whilst fructose ingestion may provide a benefit to certain athletic events, a 7 
reasonable question to ask is whether such fructose intake is detrimental to the health 8 
of athletes. Tappy and Rosset (2019) describe the potential for physical activity to 9 
protect against the negative metabolic effects of high-fructose intake, independent 10 
from total energy balance (i.e. when controlling for negative energy balance induced 11 
by exercise). Whilst high-fructose intake can increase hepatic DNL, intrahepatic fat 12 
content, hepatic insulin resistance and plasma triglyceride concentrations in sedentary 13 
individuals, all these responses can be prevented under conditions of high physical 14 
activity (Tappy & Rosset, 2019). Fructose ingested during conditions of high energy 15 
output is thought to be directed more to lactate and glucose for utilisation as a fuel by 16 
skeletal muscle, and less to triglycerides via DNL. The authors therefore speculate 17 
that the negative metabolic health consequences of high-fructose intake occur when 18 
fructose intake exceeds the capacity of the liver to release lactate and glucose for 19 
skeletal muscle to utilise (Tappy & Rosset, 2019). This may be more likely to occur 20 
under conditions of low energy output, where skeletal muscle utilisation of circulating 21 
glucose and lactate is low. The authors propose that this could contribute to regulating 22 
hepatic fructose metabolism via a feedback mechanism that is yet to be definitely 23 
established. 24 
Hengist et al. (2019) discuss a further potential mechanism that could explain 25 
the protection against fructose-induced metabolic impairments conferred by high 26 
levels of physical activity. Hepatic glycogen content plays a key role in regulating 27 
hepatic lipid metabolism by acting on both DNL and on hepatic fatty acid oxidation 28 
(Hengist et al., 2019). Hengist et al. (2019) discuss the evidence that suggests 29 
“pushing” glucose into the liver and saturating liver glycogen concentrations increases 30 
DNL and hypertriglyceridaemia, whereas increasing the inherent capacity for liver 31 
glycogen storage does not detrimentally alter plasma triglyceride concentrations. This 32 
is consistent with the notion that net lipid synthesis is exacerbated when glycogen 33 
stores are saturated. Therefore, under conditions where hepatic glycogen stores are 34 
low, or are undergoing an increased rate of turnover, there is likely to be lower rates 1 
of hepatic DNL and increased rates of hepatic fatty acid oxidation. The net result is 2 
less lipid synthesis. Furthermore, this may contribute to the mechanisms explaining 3 
why fructose can stimulate lipid synthesis to a greater extent than glucose, since 4 
fructose potently stimulates hepatic glycogen synthesis at rest and post-exercise 5 
(Petersen et al., 2001; Fuchs et al., 2016). Hepatic glycogen status may thereby 6 
provide a key link between the energy status of an individual and the metabolic 7 
responses to fructose intake. 8 
 In summary, this collection of review articles illuminates several key aspects of 9 
fructose metabolism. It is clear that excessive fructose intakes in sedentary individuals 10 
can induce a number of metabolic effects that may be detrimental to health. Whether 11 
males or females are more sensitive to the effects of fructose intake remains to be 12 
established. The hormone FGF21 could hold promise in reducing the levels of fructose 13 
intake when a high-fructose intake is undesirable and could therefore contribute to 14 
improvements in metabolic health. The metabolic effects of fructose ingestion can be 15 
utilised to benefit endurance performance and recovery in athletes, and these athletes 16 
seem to be protected against the negative metabolic effects of high-fructose intake. 17 
The mechanisms underlying exercise-induced protection against these metabolic 18 
effects remains to be established but may involve the greater conversion of fructose 19 
into glucose and lactate for oxidation rather than conversion into lipid, and these 20 
processes could be regulated by hepatic glycogen content. These physiological 21 
mechanisms provide a better understanding of why specific populations seem to be 22 
more or less vulnerable to high-fructose intakes and can be targeted for improving 23 
metabolic health. 24 
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